Talk to your doctor or pharmacist before using Otrivin Dual Relief.
Otrivin Dual Relief must be administered with caution to patients with:
- Hypertension, cardiovascular diseases
- Hyperthyroidism, diabetes mellitus
- Hypertrophy of the prostate, stenosis of the bladder bar
- Pheochromocytoma
Caution is recommended in patients predisposed to:
- Angle closure glaucoma
- Epistaxis (e.g. elderly)
- Paralytic ileus
- Cystic fibrosis
Immediate hypersensitivity including urticaria, angioedema, rash, bronchospasm, pharyngeal oedema and anaphylaxis may occur. These symptoms may appear individually or all combined as a severe allergic reaction. If this occurs, immediately STOP using Otrivin Dual Relief. The medicinal product must be used with caution in patients who are sensitive to adrenergic substances, which may give symptoms such as sleeping disturbances, dizziness, tremor, cardiac arrythmias or elevated blood pressure.
The treatment duration should not exceed 7 days, as chronic treatment with xylometazoline hydrochloride may cause swelling of the nasal mucosa and hypersecretion because of increased sensibility in the cells, ”rebound effect” (rhinitis medicamentosa). Patients should be instructed to avoid spraying Otrivin Dual Relief in or around the eye. If Otrivin Dual Relief gets in contact with the eyes, the following may occur: temporary blurred vision, irritation, pain, red eyes. Aggravation of angle closure glaucoma may also develop. The patient should be instructed to rinse their eyes with cold water if Otrivin Dual Relief gets in direct contact with the eyes and to contact a doctor if they experience pain in the eyes or blurred vision.